Pharmaceutical Preparations · DE · CIK 1787400
Nkarta, Inc. develops allogeneic, off-the-shelf engineered natural killer cell therapies for patients
Comparable business profile · signals at a glance
In the 90 days to Jan 15, 2026: 2 sold $66K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 15, 2026 | Hastings Paul JChief Executive Officer | Sell | 26,046 | $2.07 | $54K |
| Jan 15, 2026 | Mahmood NadirPresident | Sell | 5,649 | $2.07 | $12K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.